Correction to: Nature Communications https://doi.org/10.1038/s41467-020-17487-9, published online 27 July 2020.
The original version of this Article omitted the following from the Acknowledgements:
“We are grateful to Janos Tibor Kodra and Jette Lenstrup, both of Novo Nordisk A/S, who conceived and provided the OI216 insulin analogue. Furthermore, we are appreciative of Inger Lautrup-Larsen, Novo Nordisk A/S, contributions with recombinant expressing, as well as many colleagues’ producing, purifying and quantifying the compounds used in this study”.
This has now been corrected in both the PDF and HTML versions of the Article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Hubálek, F., Refsgaard, H.H.F., Gram-Nielsen, S. et al. Author Correction: Molecular engineering of safe and efficacious oral basal insulin. Nat Commun 11, 4232 (2020). https://doi.org/10.1038/s41467-020-18106-3
Published:
Version of record:
DOI: https://doi.org/10.1038/s41467-020-18106-3
